Stocks TelegraphStocks Telegraph
Stock Ideas

ORKA Financial Statements and Analysis

NASDAQ : ORKA

Oruka Therapeutics

$27.86
1.46+5.53%
At Close 4:00 PM

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSD
calendar year202520252025
periodQ3Q2Q1
revenue000
cost of revenue000
gross profit000
gross profit ratio000
research and development expenses28.988M24.087M19.925M
general and administrative expenses5.117M4.342M5.161M
selling and marketing expenses000
selling general and administrative expenses5.117M4.342M5.161M
other expenses000
operating expenses34.105M28.429M25.086M
cost and expenses34.105M28.429M25.086M
interest income3.832M3.857M4.092M
interest expenseN/A00
depreciation and amortization20.00K19.00K16.00K
ebitda-30.257M-24.555M-20.983M
ebitda ratio000
operating income-34.105M-28.429M-25.086M
operating income ratio000
total other income expenses net3.828M3.855M4.087M
income before tax-30.277M-24.574M-20.999M
income before tax ratio000
income tax expense000
net income-30.277M-24.574M-20.999M
net income ratio000
eps-0.69-0.58-0.50
eps diluted-0.69-0.58-0.50
weighted average shs out44.067M42.233M41.68M
weighted average shs out dil44.067M42.233M41.68M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSD
calendar year202520252025
periodQ3Q2Q1
cash and cash equivalents91.253M65.396M83.572M
short term investments257.902M263.01M265.522M
cash and short term investments349.155M328.406M349.094M
net receivables000
inventory000
other current assets6.008M3.606M2.989M
total current assets355.163M332.012M352.083M
property plant equipment net2.222M2.25M973.00K
goodwill000
intangible assets000
goodwill and intangible assets000
long term investments151.763M23.053M23.953M
tax assets000
other non current assets103.00K103.00K102.999K
total non current assets154.088M25.406M25.029M
other assets000
total assets509.251M357.418M377.112M
account payables2.208M4.664M3.545M
short term debt419.00K660.00K283.00K
tax payables000
deferred revenue000
other current liabilities18.34M6.786M7.895M
total current liabilities20.967M12.11M11.723M
long term debt1.493M1.666M664.00K
deferred revenue non current000
deferred tax liabilities non current000
other non current liabilities000
total non current liabilities1.493M1.666M663.999K
other liabilities000
capital lease obligations1.912M2.326M947.00K
total liabilities22.46M13.776M12.387M
preferred stock2.931M2.931M2.931M
common stock48.00K37.00K37.00K
retained earnings-159.574M-129.297M-104.723M
accumulated other comprehensive income loss185.00K-27.00K-6.00K
other total stockholders equity643.201M469.998M466.486M
total stockholders equity486.791M343.642M364.725M
total equity486.791M343.642M364.725M
total liabilities and stockholders equity509.251M357.418M377.112M
minority interest000
total investments409.665M286.063M289.475M
total debt1.912M2.326M947.00K
net debt-89.341M-63.07M-82.625M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSD
calendar year202520252025
periodQ3Q2Q1
deferred income tax000
stock based compensation05.077M0
change in working capital1.965M-2.289M-3.034M
accounts receivables000
inventory000
accounts payables0421.00K83.00K
other working capital1.965M-2.71M-3.117M
other non cash items6.69M-1.378M3.148M
net cash provided by operating activities-21.602M-23.145M-20.869M
investments in property plant and equipment-99.00K-34.00K-13.00K
acquisitions net000
purchases of investments0-107.999M-44.29M
sales maturities of investments0112.893M87.169M
other investing activites-122.35M00
net cash used for investing activites-122.449M4.86M42.866M
debt repayment000
common stock issued0109.00K0
common stock repurchased000
dividends paid000
other financing activites169.908M00
net cash used provided by financing activities169.908M109.00K0
effect of forex changes on cash000
net change in cash25.857M-18.176M21.997M
cash at end of period91.253M65.396M83.572M
cash at beginning of period65.396M83.572M61.575M
operating cashflow-21.602M-23.145M-20.869M
capital expenditure-99.00K-34.00K-13.00K
free cash flow-21.701M-23.179M-20.882M
Graph

Frequently Asked Questions

How did Oruka Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ORKA generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Oruka Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Oruka Therapeutics, Inc. reported a $0.00 Gross Profit for the quarter ended Sep 30, 2025.
Have ORKA's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ORKA incurred $34.11M worth of Operating Expenses, while it generated -$34.11M worth of Operating Income.
How much Net Income has ORKA posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Oruka Therapeutics, Inc., the company generated -$30.28M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Oruka Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Oruka Therapeutics, Inc. as of the end of the last quarter was $91.25M.
What are ORKA's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ORKA had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Oruka Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ORKA were $355.16M, while the Total Assets stand at $509.25M.
As of the last quarter, how much Total Debt did Oruka Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ORKA's debt was $1.91M at the end of the last quarter.
What were ORKA's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ORKA reported total liabilities of $22.46M.
How much did ORKA's Working Capital change over the last quarter?
Working Capital Change for ORKA was $1.97M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
ORKA generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ORKA generated -$21.60M of Cash from Operating Activities during its recently reported quarter.
What was ORKA's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ORKA reported a $25.86M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph